Go to the list of all blogs
Sergey Savastiouk's Avatar
published in Blogs
Nov 19, 2026
TickeronGET DAILY SIGNALS
Why Is InnovAge Holding Corp. (INNV) Stock Down -7.41% Today?

Why Is InnovAge Holding Corp. (INNV) Stock Down -7.41% Today?

Key Takeaways

  • Shares of INNV fell 7.41% to $8.25 in Thursday morning trading, deepening a 5.41% decline from the prior session.
  • The primary catalyst was the company's disclosure that it executed a settlement agreement with the U.S. Department of Justice and participating states, paying roughly $37 million to resolve civil claims tied to alleged conduct between 2016 and 2022.
  • The $37 million outlay and the pending resolution had already been flagged in regulatory filings in September and November, so the formal announcement carried limited new information.
  • Secondary driver: profit-taking. The stock was still up more than 80% year to date before Thursday's slide and remains roughly 35% below its 52-week high of $12.64.
  • The move was company-specific in character and came on volume running above the stock's roughly 426,000-share daily average.
  • News Significance Score: 46/100 — Moderate but largely pre-disclosed legal news, amplified by a decline nearly four times the stock's typical daily swing.
  • Traders are watching whether the $8.68 low holds, the pace of participant census growth, and the fiscal second-quarter report expected in early February.
  • For deeper research on INNV, explore Price Targets, Earnings, and Forecast pages on Tickeron.
  • Readers looking for systematic strategy ideas can explore Trending AI Robots.

Opening Summary

InnovAge Holding Corp. (INNV) is a Denver-based healthcare provider that manages care for frail, predominantly dual-eligible seniors through the Program of All-inclusive Care for the Elderly (PACE), operating 20 centers across six states and serving about 8,420 participants. Shares were trading at $8.25 on Thursday morning, down 7.41% from Wednesday's close of $8.91 — a decline of $0.66. The stock moved lower despite the company's announcement of a legal settlement that it framed as closing a difficult chapter, a reaction markets typically reserve for news that has already been absorbed. The immediate driver was the resolution of the long-running Department of Justice civil matter, announced after Wednesday's close, but the substance of the settlement had been disclosed in prior filings.

Legal Resolution Arrives With Little Surprise Value

After the closing bell on Wednesday, InnovAge said it had executed a settlement agreement with the Department of Justice and participating states resolving civil claims concerning historical practices at the company. The company paid approximately $37 million to resolve all federal and state claims relating to alleged conduct from 2016 to 2022, without admitting wrongdoing or liability. Chief Executive Patrick Blair called the resolution a closing of "an important chapter."

The catch for shareholders is timing. InnovAge had already disclosed the pending matter and the approximate payment figure in regulatory filings on September 9 and November 3, meaning the cash outlay was known and largely reflected in expectations ahead of the formal announcement. When a resolution arrives with the dollar amount already public, the incremental information is limited, and there is no upward earnings revision to follow. That dynamic is consistent with the pattern seen this week: the stock fell 5.41% on Wednesday before the announcement, then extended those losses on Thursday.

Profit-Taking After a Strong Run

The second factor is positioning. Even after Thursday's drop, INNV is up more than 80% year to date and roughly 90% over the past twelve months, having traded as low as $4.70 within the last year. The shares reached a 52-week high of $12.64 in the summer, then pulled back sharply in late September, and had recovered toward $9.60 in mid-November. That recovery gave short-term holders a substantial gain to protect, and a resolved legal overhang removes both a risk and a reason to stay positioned for the next headline. The stock now trades about 12% below its 50-day average near $9.40, a technical deterioration that likely encouraged further selling.

Cash, Capital Allocation, and Valuation

The settlement also sharpens attention on how InnovAge funds its next phase of growth, which management calls InnovAge 3.0 — investments in clinical infrastructure, Epic-based systems, analytics, new center applications such as Bakersfield, California, and potential acquisitions. The company ended the September quarter with roughly $119 million in cash plus short-term investments, and the $37 million payment was made before the announcement, so the balance sheet impact is not new. Still, the market is now weighing a leaner cash cushion against a valuation near 1.2 times annual revenue and a trailing multiple well above the healthcare provider median.

Market Context and Trading Activity

Trading activity has been elevated. Wednesday's session saw more than 500,000 shares change hands, well above the stock's roughly 426,000-share daily average, and Thursday's selling continued at an active pace. The decline was company-specific in character rather than a reflection of broad sector direction, and it pushed the shares decisively below their 50-day average. The session low of $8.68 is now the first reference point for support; a decisive break below that level would put the late-September base near $8.80–$8.80 in focus, while a reclaim of $9.00 would suggest the selling was largely technical.

News Significance Score

The score runs from 0, meaning no meaningful news and a normal move for the stock, to 100, meaning transformative news and a rare, extreme price move. INNV earns 46 out of 100. The verified news is moderate: a $37 million legal settlement is material for a company of this size, but the amount and the pending resolution had already been disclosed, so the announcement carried little surprise. The price move was approximately four times the stock's average absolute daily change of 1.9% over the past 60 sessions, and only twice in that window did the shares move as much or more. Strong but anticipated news combined with an unusual move produces the mid-range score.

What Comes Next for INNV

Attention shifts to fiscal second-quarter results, expected in early February, with consensus centered near $0.10 per share. Investors will focus on participant census, which grew 6.7% year over year to 8,420, center-level contribution margin, which reached 24.0% of revenue, and adjusted EBITDA, which rose sharply to $31.3 million last quarter. Also relevant: the ramp of the Pennsylvania center conversions, progress on the Bakersfield application, and any commentary on rate updates and utilization trends. Risks include the inherently lumpy nature of rate timing and utilization, execution risk on new center openings, continued insider selling, and the possibility that legal costs or reputational scrutiny linger despite the settlement.

Trending AI Robots

Tickeron's Trending AI Robots page offers a curated view of the platform's strongest automated strategies. Tickeron maintains hundreds of AI trading bots covering thousands of tickers, but only those performing best under current market conditions are featured here. Bots differ widely by strategy, timeframe, performance metrics, and the symbols they trade. For readers who want to see which automated approaches are working right now, the page is a useful starting point — explore the current lineup and compare strategies against your own research.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: INNV

Contributor

Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.


Aroon Indicator for INNV shows an upward move is likely

INNV's Aroon Indicator triggered a bullish signal on November 06, 2026. Tickeron's A.I.dvisor detected that the AroonUp green line is above 70 while the AroonDown red line is below 30. When the up indicator moves above 70 and the down indicator remains below 30, it is a sign that the stock could be setting up for a bullish move. Traders may want to buy the stock or look to buy calls options. A.I.dvisor looked at 176 similar instances where the Aroon Indicator showed a similar pattern. In 147 of the 176 cases, the stock moved higher in the days that followed. This puts the odds of a move higher at 84%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 59 of 72 cases where INNV's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 82%.

The Momentum Indicator moved above the 0 level on November 20, 2026. You may want to consider a long position or call options on INNV as a result. In 86 of 114 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 75%.

Following a +1.92% 3-day Advance, the price is estimated to grow further. Considering data from situations where INNV advanced for three days, in 226 of 277 cases, the price rose further within the following month. The odds of a continued upward trend are 82%.

Bearish Trend Analysis

The Moving Average Convergence Divergence Histogram (MACD) for INNV turned negative on November 19, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 50 similar instances when the indicator turned negative. In 45 of the 50 cases the stock turned lower in the days that followed. This puts the odds of success at 90%.

INNV moved below its 50-day moving average on November 17, 2026 date and that indicates a change from an upward trend to a downward trend.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where INNV declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 84%.

INNV broke above its upper Bollinger Band on November 04, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of 2 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (5.195) is normal, around the industry mean (204.532). INNV's P/E Ratio (-448.500) is considerably lower than the industry average of (21.572). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.498). Dividend Yield (0.000) settles around the average of (0.153) among similar stocks. P/S Ratio (1.488) is also within normal values, averaging (2.688).

The Tickeron Price Growth Rating for this company is 42 (best 1 - 100 worst), indicating steady price growth. INNV’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is 70 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. INNV’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 83, placing this stock better than average.

The Tickeron SMR rating for this company is 91 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is 100 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

Notable companies

The most notable companies in this group are DaVita (NYSE:DVA), Community Health Systems (NYSE:CYH), WW International Inc (NASDAQ:WW).

Industry description

Hospital/Nursing Management companies own and operate health care facilities. Their operations include nursing homes, acute care facilities, retirement centers and outpatient surgery centers. HCA Healthcare Inc., Alcon Inc. and Universal Health Services, Inc. are some major companies in this industry. Technology has been at the forefront of development of advanced solutions, including quicker diagnoses of complex conditions. Investments in new diagnostics, healthcare IoT, and other healthcare technologies continue to gather momentum in this industry.

Market Cap

The average market capitalization across the Hospital/Nursing Management Industry is 5.37B. The market cap for tickers in the group ranges from 20.9K to 107.17B. HCA holds the highest valuation in this group at 107.17B. The lowest valued company is NMMCF at 20.9K.

High and low price notable news

The average weekly price growth across all stocks in the Hospital/Nursing Management Industry was -12%. For the same Industry, the average monthly price growth was -12%, and the average quarterly price growth was 0%. CHE experienced the highest price growth at 0%, while NIVF experienced the biggest fall at -88%.

Volume

The average weekly volume growth across all stocks in the Hospital/Nursing Management Industry was 13%. For the same stocks of the Industry, the average monthly volume growth was 102% and the average quarterly volume growth was 58%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 52
P/E Growth Rating: 49
Price Growth Rating: 59
SMR Rating: 66
Profit Risk Rating: 83
Seasonality Score: -4 (-100 ... +100)
Trend Prediction Engine 4
View a ticker or compare two or three
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

Industry HospitalNursingManagement

Industry
N/A
Address
8950 East Lowry Boulevard
Phone
+1 844 803-8745
Employees
2500
Web
https://www.innovage.com
Interact to see
Advertisement
SDD is an inverse leveraged ETF (exchange-traded fund) built to return roughly -2x the daily move of the S&P SmallCap 600 Index, making it a tactical hedging tool rather than a long-term holding. XXX is an asset-allocation ETF that blends roughly 75% S&P 500 large-cap equities with a 25% sleeve of XRP, a major cryptocurrency, aiming for capital appreciation.
AMD jumped +2.42%, rising $12.81 to $542.95 from Wednesday's close of $530.14, in early regular-session trading Thursday after extending gains built during premarket. The catalyst was Anthropic's IPO, priced at $83 a share above its marketed range and raising $81.3 billion in the largest listing on record; the debut revived sentiment across AI hardware names, and AMD is both an Anthropic supplier and a $2.5 billion investor in the lab.
ROM is an established, leveraged exchange-traded fund (ETF) that targets twice (2x) the daily return of the S&P Technology Select Sector Index, while XXX is a recently launched blended ETF pairing large-cap U.S. equities with XRP exposure. ROM benefits from deep liquidity and roughly $1.1 billion in AUM (assets under management); XXX remains far smaller, with assets measured in the hundreds of thousands of dollars.
NVIDIA (NVDA) has declined roughly 32.6% over the last 30 days, falling from $216.47 on October 20 to around $146 in mid-November trading. The selloff was triggered by the surprise resignation of founder and CEO Jensen Huang, along with governance, regulatory, and China-related concerns.
Micron shares slid from Thursday's $690.44 close to $635.41, a -7.97% loss, deepening during Friday's regular session after an already soft premarket. The decline was sector-driven, not company-specific: investors kept unwinding AI exposure as Anthropic fell back after its debut, while hawkish Fed comments and doubts about Nvidia's leadership and AI spending returns pressured chip valuations.